| 7.39 0.78 (11.8%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.63 |
1-year : | 10.08 |
| Resists | First : | 7.38 |
Second : | 8.63 |
| Pivot price | 6.12 |
|||
| Supports | First : | 6.04 |
Second : | 5.21 |
| MAs | MA(5) : | 6.52 |
MA(20) : | 6.04 |
| MA(100) : | 4.6 |
MA(250) : | 5.23 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 96 |
D(3) : | 86.7 |
| RSI | RSI(14): 76 |
|||
| 52-week | High : | 10 | Low : | 2.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRVS ] has closed It is unclear right now based on current values. 67% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.39 - 7.42 | 7.42 - 7.44 |
| Low: | 6.48 - 6.5 | 6.5 - 6.53 |
| Close: | 7.34 - 7.38 | 7.38 - 7.43 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Thu, 25 Sep 2025
Are Investors Undervaluing Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) By 37%? - 富途牛牛
Thu, 11 Sep 2025
American Century Companies Inc. Has $284,000 Stake in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Tue, 12 Aug 2025
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha
Thu, 31 Jul 2025
Clinical-Stage Biotech Corvus Pharmaceuticals Sets Q2 2025 Earnings Release: Key Updates Coming August 7 - Stock Titan
Thu, 24 Jul 2025
Corvus Pharma Bets On Immunotherapy And Analyst Optimism - Finimize
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 75 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 56.2 (%) |
| Shares Short | 9,590 (K) |
| Shares Short P.Month | 8,790 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -68.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -6.72 |
| PEG Ratio | 0 |
| Price to Book value | 6.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|